Genmab Drug Combo Cuts DLBCL Progression/Death Risk by 51% in Phase 3

Genmab reported topline Phase 3 data showing epcoritamab plus R-CHOP reduced the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed DLBCL patients.